2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Chimeric Antigen Receptor, Gene Therapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Hemophilia, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Autoimmune Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Animal Model
PAPER

2547 Genome editing with all-RNA targeted lipid nanoparticles enables in vivo editing of hematopoietic stem cells for sickle cell disease and T cells for CAR-T applications

Mohit Gupta, PhD, Rahul Palchaudhuri, PhD2, Michael Monte3, Han Gu, PhD4, Jonny Le5, Lei Liu, PhD6, Samuele Mezzetti, MS7, Aaron Zannini8, Sarah L Benson9, Giulia Schiroli, PhD10, Lorenzo Tozzi, PhD11, Thomas V Colace, PhD12, Gun Su Han, PhD13, Apiwat Wangweerawong, PhD14, Rebecca Levy, MS15, Trine A Kristiansen, PhD16, Drishti Parwanda, MS17, Nouhaila Beytour, MS18, Donghui Li, PhD19, Ninad Kumbhojkar, PhD20, Chauncey Zeng, PhD21, Jessica Desmond, MS22, Alberto De Iaco, PhD23, Jeff Ann, PhD24, Pinky Htun, MS25, Gang Sun, PhD26, Ulrike Gerdemann, MD27, Francesca Alvarez Calderon, MD, PhD28, Lev Gorfinkel, MD29, Kristin Rathje, MD30, Leslie Kean, MD, PhD31, So Gun Hong, PhD32, Naoya Uchida, MD, PhD33, Robert E Donahue, DVM34, John Tisdale, MD35, Luciano Apponi, PhD36, Anne Bothmer, PhD37, Francis Pierciey, MS38, Cecilia Cotta-Ramusino, PhD39, Hari Pujar, PhD40, Michael C Holmes, PhD41, Z. Jane Wang, PhD42
1 Tessera Therapeutics, Somerville, Massachusetts, United States
2 Tessera Therapeutics, Somerville, Massachusetts, United States
3 Tessera Therapeutics, Somerville, Massachusetts, United States
4 Tessera Therapeutics, Somerville, Massachusetts, United States
5 Tessera Therapeutics, Somerville, Massachusetts, United States
6 Tessera Therapeutics, Somerville, Massachusetts, United States
7 Tessera Therapeutics, Somerville, Massachusetts, United States
8 Tessera Therapeutics, Somerville, Massachusetts, United States
9 Tessera Therapeutics, Somerville, Massachusetts, United States
10 Tessera Therapeutics, Somerville, Massachusetts, United States
11 Tessera Therapeutics, Somerville, Massachusetts, United States
12 Tessera Therapeutics, Somerville, Massachusetts, United States
13 Tessera Therapeutics, Somerville, Massachusetts, United States
14 Tessera Therapeutics, Somerville, Massachusetts, United States
15 Tessera Therapeutics, Somerville, Massachusetts, United States
16 Tessera Therapeutics, Somerville, Massachusetts, United States
17 Tessera Therapeutics, Somerville, Massachusetts, United States
18 Tessera Therapeutics, Somerville, Massachusetts, United States
19 Tessera Therapeutics, Somerville, Massachusetts, United States
20 Tessera Therapeutics, Somerville, Massachusetts, United States
21 Tessera Therapeutics, Somerville, Massachusetts, United States
22 Tessera Therapeutics, Somerville, Massachusetts, United States
23 Tessera Therapeutics, Somerville, Massachusetts, United States
24 Tessera Therapeutics, Somerville, Massachusetts, United States
25 Tessera Therapeutics, Somerville, Massachusetts, United States
26 Tessera Therapeutics, Somerville, Massachusetts, United States
27 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
28 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
29 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
30 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
31 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
32 NHLBI/NIH, Bethesda, Maryland, United States
33 NHLBI/NIH, Bethesda, Maryland, United States
34 NHLBI/NIH, Bethesda, Maryland, United States
35 NHLBI/NIH, Bethesda, Maryland, United States
36 Tessera Therapeutics, Somerville, Massachusetts, United States
37 Tessera Therapeutics, Somerville, Massachusetts, United States
38 Tessera Therapeutics, Somerville, Massachusetts, United States
39 Tessera Therapeutics, Somerville, Massachusetts, United States
40 Tessera Therapeutics, Somerville, Massachusetts, United States
41 Tessera Therapeutics, Somerville, Massachusetts, United States
42 Tessera Therapeutics, Somerville, Massachusetts, United States

Non-viral in vivo genetic medicines potentially promise novel curative therapies with broader patient access than ex vivo gene therapy. Their success depends on delivery vehicles that safely and efficiently transport gene-modifying payloads to intended cells. While lipid nanoparticles (LNPs) have shown clinical validation for RNA delivery to the liver, extending them to extrahepatic tissues remains a challenge. Tessera Therapeutics’ approach is designed to pair optimized cell- and tissue-tropic LNPs with its RNA-based Gene Writing platform to enable in vivo editing of target cells, including extra-hepatic cells, directly in the body. Our Gene Writers are designed to use target-primed reverse transcription to perform edits ranging from single-nucleotide corrections to whole-gene insertions. Delivery to long-term hematopoietic stem cells (LT-HSCs) enables a path to address sickle cell disease (SCD), where our Gene Writers intend to make a single-nucleotide correction of the disease-causing β-globin mutation. Delivery to T cells opens a path to in vivo chimeric antigen receptor (CAR)-T cells, where our Gene Writers intend to permanently insert a CAR gene, with applications across oncology and autoimmune disease.

Our LNP design integrates multiple strategies for tissue-tropic delivery, including optimized ionizable lipid chemistry, customized lipid ratios to skew biodistribution and enhance endosomal escape, and cell-specific targeting ligands for selective cellular uptake. We first optimized in vivo HSC delivery using surrogate payloads, a transient GFP reporter and β-2 microglobulin (β2M) editors. Targeting ligands were selected by screening a panel of HSC surface receptors and candidates were nominated following in vivo readouts. Receptor identity alone was insufficient, and co-optimization of targeting ligand and formulation was required to achieve therapeutic levels of delivery and editing. In B6 mice, a single intravenous dose of an HSC-targeted LNP reduced liver GFP expression 11-fold versus a liver-tropic LNP, while HSC-targeting elements increased bone marrow GFP delivery 55-fold with minimal liver expression. In cynomolgus macaques, our LNPs demonstrated improved delivery to HSCs, achieving three-fold greater β2M editing in bone marrow versus liver and a nearly two-fold longer blood half-life than liver-tropic LNPs.

We next advanced to the SCD-relevant β-globin gene edit. A single intravenous dose of an optimized HSC-targeted LNP installed the Makassar β-globin as a surrogate edit (E6A; glutamate-to-alanine at codon 6) in an average of 85% of LT-HSCs in cynomolgus macaques and 87% of LT-HSCs in rhesus by single-cell analysis. These levels exceed the 20-30% edited HSC threshold associated with meaningful clinical benefit for SCD and are within the range of editing and transduction levels reported with approved ex vivo gene therapies. Longitudinal studies in non-human primates (NHP) showed that editing in LT-HSCs and hematopoietic stem and progenitor cells (HSPCs) remained stable and evenly distributed across bone marrow lineages out to ~19 months.

Toward in vivo CAR-T therapies, we are developing T cell-targeted LNPs designed to deliver our Gene Writers to permanently integrate a CAR gene into the T-cell genome. We used a CD20-directed CAR as our model construct, enabling B-cell depletion readouts in both humanized mice and NHPs. In naïve CD34+ humanized NSG mice, a single dose as low as 0.03 mpk of T cell-targeted LNP with Gene Writer and CD20 CAR template successfully generated functional CAR+ T cells in vivo and resulted in the elimination of circulating human B-cells, with immunohistochemistry confirming splenic B-cell clearance. Advancing to NHPs, single low doses (0.02, 0.05 or 0.1 mpk) of our CD20 CAR Gene Writer with our T cell targeted LNP drove robust peripheral B cell depletion for up to 35 days. Immunohistochemistry further supported robust B-cell depletion in lymph nodes. Gene Writer integration was restricted to T-cells, with 1-2 transgene copies per T-cell. Biodistribution analysis across 32 tissues in the NHP receiving the highest dose (0.1 mpk) showed no detectable editing in liver, HSCs or other off-target organs.

Together, these results highlight the potential of our extrahepatic LNP delivery and Gene Writer platforms to provide scalable, off-the shelf therapies by enabling the efficient editing of LT-HSCs and T cells in vivo.

Mohit Gupta, PhD: No relevant conflicts of interest to declare.